NCT01320085 - A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

March 24, 2011

Primary Completion Date

January 7, 2014

Study Completion Date

February 6, 2023

Conditions

BRAF or NRAS Mutant Metastatic Melanoma

Interventions

DRUG

MEK162

Trial Locations (25)

16132

Istituto nazionale Per la Ricerca sul Cancro, Genova

18015

Cancer Care Associates Medical Oncology, Bethlehem

St. Luke's University Health Network, Bethlehem

18104

Cancer Care Associates Medical Oncology, Allentown

St. Luke's Cancer Center - Allentown Campus, Allentown

18951

St. Luke's Hospital - Quakertown Campus, Quakertown

23562

Universitatsklinikum Schleswig-Holstein, Lübeck

24105

Universitatsklinikum Schleswig-Holstein, Kiel

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

45122

Universitätsklinikum Essen, Essen

80131

Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale, Napoli

80337

LMU Klinikum der Universität, Munich

LMU Klinikum der Universität München, München

LMU Klinikum der Universität München, Munich

97201

OHSU Knight Cancer Institute, Portland

97239

OHSU Center for Health and Healing, Portland

Oregon Health and Science University, Portland

72703-4005

Highlands Oncology Group, Fayetteville

D-24105

Universitatsklinikum Schleswig-Holstein, Kiel

07548

SRH Wald-Klinikum Gera GmbH, Gera

6525 GA

Radboud University Nijmegen Medical Centre, Nijmegen

6229 HX

Maastricht University Medical Center, Maastricht

1066 CX

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

1066 EC

Slotervaartziekenhuis, Amsterdam

08091

Universitätsspital Zürich, Zürich (de)